Replies to post #274403 on NorthWest Biotherapeutics Inc (NWBO)

[scotty3371]

Duffy most likely left when Linda explained her business model to him. She tried to explain with only 30 dilutions every year they can kick the can down the road til 2025 and all be very rich.

Duffy was not impressed with the data, that is why he left. Stock options would all be worthless.

Linda probably said it would be excruciating for anyone to ever miss a paycheck under her watch.

[Sojourner55]

He does not strike me as a gambler

Exactly and why would he move over to this tiny startup without a single approved product and a clinical trial with unknown results even though it may look good with the blinded data. I've said at the beginning his move may be predicated on something else other than a career move. I have no doubt with his experience and qualifications he probably find a job with no difficulty but why take the risk. What is there to collaborate on when DCVax is not yet proven (TLD).?

[Looking4aprofit]

I don’t buy that rationale.
Don’t you think our Harvard lawyers would not have made him sign NDAs and Non Competes?
After he leaves nwbo, he joins a BP and that nwbo did not file an injunction to prevent him from being re-employed by a BP, no less by Merck?
Merck takes him back knowing full well of his possible contractual obligations?
Isn’t it “coincidental” that Duffy’s experience included helping in FDA submissions for drug approvals? We had hit a pause in our SAP submission when he “joined” 6 months ago. After that it was speculated that we had submitted the final SAP?
Isn’t it convenient that Duffy left a month ago and a PR is released that we are in for “interesting” times?
Wouldn’t it be interesting if he could have done DD / “helping” from within as an employee and after a 6month “secondment” to nwbo he gets re-employed at no loss of position by Merck?
Could it be that the “offer he could not refuse” was that he would head up the JV entity for the commercialisation of DC technology?

Join the dots guys!!

Btw, what happened to the chorus of naysayers ....he was fired by Merck?

Interesting that we ended up in the “green” when this news broke on social media?
Has Mr. Market spoken that he likes the development?

Hmmmm....interesting times ahead!!

[CherryTree1]

Your underlying assumption is that his move to Merck was his own initiative and was not done in partnership with Merck:

If NWBO were pioneering a fundamental sea change in the way solid tumors are treated and the results were undeniable, why would you leave?

He may have simply been asked by Merck to make a temporary move to NWBO to help them navigate the regulatory hurdles. If he already knew many of the FDA folks from his work at Merck they might be more receptive to him, but that would only be the case with him working for NWBO not as a 3rd party still working for Merck. It could very well be that he has accomplished what he was asked to do and that would also explain why he is returning to what appears to be essentially the same position at Merck. That's my 2 cents.

[Biotemptation]

I agree Umibe

[learningcurve2020]

I can give you the simplest explanation in one sentence:

He was loaned out as part of the pump hoping to raise much more cash than they did.

[manibiotech]

This is the most logical explanation